472 related articles for article (PubMed ID: 27757797)
1. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Heyne N; Denecke B; Guthoff M; Oehrlein K; Kanz L; Häring HU; Weisel KC
Ann Hematol; 2012 May; 91(5):729-735. PubMed ID: 22170517
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute kidney injury with cast nephropathy.
Walther C; Podoll AS; Finkel KW
Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
[TBL] [Abstract][Full Text] [Related]
6. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
[TBL] [Abstract][Full Text] [Related]
7. Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report.
Donati G; Zappulo F; Croci Chiocchini AL; Comai G; Zamagni E; La Manna G
Hemodial Int; 2019 Jul; 23(3):E97-E99. PubMed ID: 30791209
[TBL] [Abstract][Full Text] [Related]
8. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
9. Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney.
Donati G; Zappulo F; Maietti E; Scrivo A; Gasperoni L; Zamagni E; Tacchetti P; Pantani L; Baraldi O; Comai G; Cappuccilli M; Cavo M; La Manna G
Toxins (Basel); 2022 Jun; 14(6):. PubMed ID: 35737052
[TBL] [Abstract][Full Text] [Related]
10. The role of immunological assessment in patients with acute kidney injury and possible myeloma.
Lachmann HJ; Wassef NL
Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638
[TBL] [Abstract][Full Text] [Related]
11. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
[TBL] [Abstract][Full Text] [Related]
12. Management of acute kidney injury in symptomatic multiple myeloma.
Bridoux F; Leung N; Belmouaz M; Royal V; Ronco P; Nasr SH; Fermand JP;
Kidney Int; 2021 Mar; 99(3):570-580. PubMed ID: 33440212
[TBL] [Abstract][Full Text] [Related]
13. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
Cserti C; Haspel R; Stowell C; Dzik W
Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
[TBL] [Abstract][Full Text] [Related]
14. Clinically-suspected cast nephropathy: A retrospective, national, real-world study.
Szabo AG; Thorsen J; Iversen KF; Hansen CT; Teodorescu EM; Pedersen SB; Flaeng SB; Strandholdt C; Frederiksen M; Vase MØ; Frølund UC; Krustrup D; Plesner T; Vangsted AJ
Am J Hematol; 2020 Nov; 95(11):1352-1360. PubMed ID: 32777108
[TBL] [Abstract][Full Text] [Related]
15. Plasmapheresis in cast nephropathy: yes or no?
Madore F
Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):177-82. PubMed ID: 25590785
[TBL] [Abstract][Full Text] [Related]
16. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.
Shum HP; Chan KC; Chow CC; Kho BC; Yan WW
Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429
[TBL] [Abstract][Full Text] [Related]
17. [Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Renal Impairment of Multiple Myeloma Collaborative Study Group
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):871-875. PubMed ID: 29136724
[TBL] [Abstract][Full Text] [Related]
18. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
20. Myeloma light chain cast nephropathy, a review.
Sathick IJ; Drosou ME; Leung N
J Nephrol; 2019 Apr; 32(2):189-198. PubMed ID: 29730782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
